Mechanisms and indicators of inflammasome signaling in Parkinson’s disease

帕金森病炎症小体信号传导机制和指标

基本信息

  • 批准号:
    10310571
  • 负责人:
  • 金额:
    $ 67.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-21 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY The ViCTER Consortium has been established to characterize mechanisms of inflammation in the peripheral myeloid immune compartment, determine their impact on pesticide-driven neurodegeneration, and see if plasma- borne indicators of these processes are associated with military occupation and Parkinson’s disease (PD). It is widely accepted that complex gene-environment interactions underlie the risk of PD. Our work in pesticide- exposed mice and PD patients indicates that environmental toxicants converge on the NLRP3 inflammasome. Inflammasomes are intracellular multi-protein pattern recognition complexes that initiate and propagate inflammation in response to cellular damage and stress associated with the reversible process of pyroptotic cell death. The NLRP3 inflammasome has emerged as a key mediator of inflammation in PD, in part because it can sense non-microbial inflammatory triggers commonly associated with chronic, age-related neurodegenerative disorders. NLRP3 inflammasome triggers identified in models of PD include pesticides, heavy metals, mitochondrial and oxidative stress, and proteinaceous insult. Environmental toxicant exposure is often systemic and there is a growing appreciation of the role of the peripheral immune system in the response to toxicants and the progression of PD. Characterizing PD-related mechanisms in peripheral immune cells may help to identify signatures relevant to the progression of PD. Our studies in mice systemically exposed to rotenone identify a Nlrp3-dependent peripheral immune response co-occurring with nigral neurodegeneration. Our study of PD patients identified easily detectable plasma-borne indicators of NLRP3 inflammasome activity and elevated plasma NLRP3 protein in PD patients, potentially related to military employment. These data provide a compelling backdrop for our proposed characterization of peripheral NLRP3 activity in the context of PD. We have developed innovative mouse models based on CRE-driven cell-type specific Nlrp3 gain-of-function. We will limit Nlrp3 expression to peripheral myeloid cells and characterize the peripheral immune response, neuroinflammation, and nigral neurodegeneration using an established rotenone exposure-based PD model. In a second aim, we follow up on pilot studies to determine if the anti-inflammatory neuroprotective protein Regulator of G-protein Signaling 10 (RGS10) functions to resolve NLRP3-inflammasome signaling. In a third Aim, we team with the White River Junction VA Medical Center to evaluate subjects with prior military experience, using established assays to characterize the relationship between circulating inflammasome-related proteins, military occupation, and PD. Our ViCTER Consortium brings together experts in NLRP3 and toxicant-based models of PD, RGS10 and PD-related immunology, and patient-based studies. The collaborators will employ interdisciplinary strategies to characterize clinically relevant inflammatory mechanisms and inflammasome activity in an at-risk patient population. Studies will provide a foundation for the development of diagnostic tools and therapies to monitor, stratify, and treat PD.
项目概要 ViCTER 联盟的成立是为了表征外周炎症机制 骨髓免疫区室,确定它们对农药驱动的神经变性的影响,并看看血浆是否 这些过程的指标与军事占领和帕金森病(PD)有关。这是 人们普遍认为复杂的基因-环境相互作用是帕金森病风险的基础。我们在农药方面的工作- 暴露的小鼠和 PD 患者表明环境毒物聚集在 NLRP3 炎性体上。 炎症小体是细胞内多蛋白模式识别复合物,可启动和传播 炎症反应与细胞焦亡细胞可逆过程相关的细胞损伤和应激 死亡。 NLRP3 炎症小体已成为 PD 炎症的关键介质,部分原因是它可以 感知通常与慢性、年龄相关的神经退行性疾病相关的非微生物炎症触发因素 失调。 PD 模型中发现的 NLRP3 炎症小体触发因素包括农药、重金属、 线粒体和氧化应激以及蛋白质损伤。环境毒物暴露通常是全身性的 人们越来越认识到外周免疫系统在对毒物和毒素的反应中的作用。 PD 的进展。表征外周免疫细胞中与 PD 相关的机制可能有助于识别 与 PD 进展相关的特征。我们对全身暴露于鱼藤酮的小鼠进行的研究确定了 Nlrp3 依赖性外周免疫反应与黑质神经变性同时发生。我们对PD的研究 患者发现了易于检测的血浆中 NLRP3 炎性体活性指标并升高 PD患者血浆NLRP3蛋白,可能与军事就业有关。这些数据提供了 我们提出的 PD 背景下外周 NLRP3 活性表征的令人信服的背景。我们 开发了基于 CRE 驱动的细胞类型特异性 Nlrp3 功能获得的创新小鼠模型。我们将 限制 Nlrp3 表达到外周骨髓细胞并表征外周免疫反应, 使用已建立的基于鱼藤酮暴露的 PD 模型来研究神经炎症和黑质神经变性。在 第二个目标是,我们跟进试点研究,以确定抗炎神经保护蛋白是否 G 蛋白信号传导调节器 10 (RGS10) 的作用是解析 NLRP3 炎症小体信号传导。在第三个 我们的目标是与 White River Junction VA 医疗中心合作,评估具有军事经验的受试者, 使用已建立的测定法来表征循环炎症体相关蛋白之间的关系, 军事占领和PD。我们的 ViCTER 联盟汇集了 NLRP3 和基于毒物的专家 PD、RGS10 和 PD 相关免疫学模型以及基于患者的研究。合作者将聘用 跨学科策略来表征临床相关炎症机制和炎症小体 高危患者群体中的活动。研究将为诊断工具的开发提供基础 以及监测、分层和治疗帕金森病的疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Matthew Charles Havrda其他文献

Matthew Charles Havrda的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Matthew Charles Havrda', 18)}}的其他基金

Mechanisms of pesticide-induced neuroinflammation and parkinsonism in aging mice.
农药引起衰老小鼠神经炎症和帕金森病的机制。
  • 批准号:
    10375629
  • 财政年份:
    2022
  • 资助金额:
    $ 67.32万
  • 项目类别:
Mechanisms of pesticide-induced neuroinflammation and parkinsonism in aging mice.
农药引起衰老小鼠神经炎症和帕金森病的机制。
  • 批准号:
    10569052
  • 财政年份:
    2022
  • 资助金额:
    $ 67.32万
  • 项目类别:
Mechanisms and indicators of inflammasome signaling in Parkinson’s disease
帕金森病炎症小体信号传导机制和指标
  • 批准号:
    10491765
  • 财政年份:
    2021
  • 资助金额:
    $ 67.32万
  • 项目类别:
Mechanisms and indicators of inflammasome signaling in Parkinson’s disease
帕金森病炎症小体信号传导机制和指标
  • 批准号:
    10687222
  • 财政年份:
    2021
  • 资助金额:
    $ 67.32万
  • 项目类别:
Mechanisms of rotenone-induced neuroinflammation and Parkinsonism in aging mice
鱼藤酮诱导衰老小鼠神经炎症和帕金森病的机制
  • 批准号:
    9115160
  • 财政年份:
    2015
  • 资助金额:
    $ 67.32万
  • 项目类别:
Mechanisms of rotenone-induced neuroinflammation and Parkinsonism in aging mice
鱼藤酮诱导衰老小鼠神经炎症和帕金森病的机制
  • 批准号:
    9265460
  • 财政年份:
    2015
  • 资助金额:
    $ 67.32万
  • 项目类别:
The Role of Id2 in Adult Neurogenesis
Id2 在成人神经发生中的作用
  • 批准号:
    7407036
  • 财政年份:
    2008
  • 资助金额:
    $ 67.32万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 67.32万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 67.32万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 67.32万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 67.32万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 67.32万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 67.32万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 67.32万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 67.32万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 67.32万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 67.32万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了